Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genova Biotech To Launch New Anti-cancer Drug Novaferon

This article was originally published in PharmAsia News

Executive Summary

Beijing-based Genova Biotech will complete clinical trials on its anti-cancer drug Novaferon and commence production within the year. The company disclosed that it will price the genetically engineered protein-based product at a level only one-fifth to one-tenth that of imported biopharmaceutical medicines. Although it is still in the final approval stages, the drug's projected sales could reach several billion yuan. Novaferon's anti-tumor and anti-virus activities are much higher than those of natural interferon. Trials show that the drug can inhibit the growth of cancer of the pancreas, bowel, liver, lung, breast, ovary and prostate. (Click here for more - Chinese Language)
UsernamePublicRestriction

Register

SC072101

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel